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AbstrAct
Background It is still uncertain whether coronary 
bifurcations with lesions involving a large side branch 
(SB) should be treated by stenting the main vessel and 
provisional stenting of the SB (simple) or by routine 
two- stent techniques (complex). We aimed to compare 
clinical outcome after treatment of lesions in large 
bifurcations by simple or complex stent implantation.
Methods The study was a randomised, superiority 
trial. Enrolment required a SB≥2.75 mm, ≥50% 
diameter stenosis in both vessels, and allowed 
SB lesion length up to 15 mm. The primary 
endpoint was a composite of cardiac death, non- 
procedural myocardial infarction and target lesion 
revascularisation at 6 months. Two- year clinical 
follow- up was included in this primary reporting due 
to lower than expected event rates.
Results A total of 450 patients were assigned to 
simple stenting (n=221) or complex stenting (n=229) 
in 14 Nordic and Baltic centres. Two- year follow- 
up was available in 218 (98.6%) and 228 (99.5%) 
patients, respectively. The primary endpoint of major 
adverse cardiac events (MACE) at 6 months was 5.5% 
vs 2.2% (risk differences 3.2%, 95% CI −0.2 to 6.8, 
p=0.07) and at 2 years 12.9% vs 8.4% (HR 0.63, 
95% CI 0.35 to 1.13, p=0.12) after simple versus 
complex treatment. In the subgroup treated by newer 
generation drug- eluting stents, MACE was 12.0% vs 
5.6% (HR 0.45, 95% CI 0.17 to 1.17, p=0.10) after 
simple versus complex treatment.
Conclusion In the treatment of bifurcation lesions 
involving a large SB with ostial stenosis, routine two- 
stent techniques did not improve outcome significantly 
compared with treatment by the simpler main vessel 
stenting technique after 2 years.
Trial registration number NCT01496638.
Key questions
What is already known about this subject?
 ► Previous comparisons of one- stent and two- stent 
techniques for coronary bifurcation stenting have 
shown conflicting results but indicated that most 
bifurcations with large side branches (SBs) are ef-
fectively treated by the simple provisional SB stent-
ing technique. Two- stent techniques have important 
procedural advantages in allowing for securing the 
SB first in cases with difficult SB access or high risk 
of occlusion.
What does this study add?
 ► Patients with a coronary bifurcation lesion involving 
a large side branch (SB) may be treated safely us-
ing a two- stent technique, in particular when using 
newer generation drug- eluting stents. As many pa-
tients had no need for a second stent in the simple 
provisional stenting group, future research should 
focus on evaluation of tools for identification of le-
sions requiring SB treatment.
How might this impact on clinical practice?
 ► Using newer generation drug- eluting stents, there is 
at least no penalty in treating coronary bifurcation 
lesions with two- stent techniques.
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InTRoduCTIon
Coronary bifurcations are predilection site for athero-
sclerosis due to regions of low endothelial shear stress 
resulting in pathological intimal thickening and plaque 
formation.1 Treatment of bifurcation lesions constitute 
about 15% of coronary interventions and are consequently 
of major clinical interest. Currently, the simple, provi-
sional side branch (SB) stenting technique is the recom-
mended strategy for bifurcation lesion treatment.2–8 With 
one exception,9 previous studies have shown no benefit 
of preplanned two- stent techniques in comparison to 
the simple strategy. In simple provisional SB stenting, a 
stent is deployed in the main vessel (MV) across the SB, 
and if needed, the SB is subsequently treated by balloon 
dilatation or stent implantation.10 Planned stenting of 
both MV and SB may be accomplished using a number of 
different techniques, such as T- stenting, T and protrude 
(TAP), culotte and crush techniques. In earlier studies 
on simple versus complex bifurcation stenting, inclusion 
of patients with small and possibly physiological insignif-
icant SBs was a major limitation for extending results to 
clinically important bifurcation lesions involving a large 
SB.2 4–6 10 Therefore, we designed the present study to 
address the unsolved question of simple provisional SB 
stenting versus complex two- stent treatment in patients 
with bifurcation lesions involving a large SB.
MeTHods
study design and patient selection
The Nordic Baltic Bifurcation Study IV (Nordic Baltic 
IV) was a prospective, randomised, multicentre trial 
comparing the simple provisional SB stenting technique 
versus complex stenting of both the MV and the SB in 
the treatment of coronary bifurcation lesions. A total 
of 450 patients were included from December 2008 to 
December 2012 in centres in Norway, Sweden, Finland, 
Lithuania, Latvia and Denmark. Inclusion criteria were 
stable angina pectoris, unstable angina pectoris or silent 
ischaemia, a ‘true’ bifurcation lesion (Medina 1.1.1 or 
1.0.1 or 0.1.1), lesion11 in the left anterior descending 
artery (LAD)/diagonal, circumflex artery (Cx)/obtuse 
marginal branch, right coronary artery/posterior 
descending artery/posterolateral branch, or left main 
coronary artery (LMCA)/LAD/Cx with an MV diameter 
≥3.0 mm and SB diameter ≥2.75 mm by visual estimate. 
Exclusion criteria were ST- elevation myocardial infarc-
tion within 24 hours, SB lesion length >15 mm, expected 
survival <1 year, s- creatinine >200 µmol/L, allergy to 
aspirin, clopidogrel, ticlopidine, sirolimus or everolimus. 
All patients provided written informed consent.
Randomisation procedure
When guide wires were inserted in both the MV and the 
SB, eligible patients were randomised 1:1 to the simple 
or the complex group by an independent web- based trial 
management system (TrialPartner, Public Health and 
Quality Improvement, Central Denmark Region, Aarhus, 
Denmark). Randomisation was performed in permutated 
blocks by centre with stratification according to gender, 
age>70 years, diabetes mellitus and participation in the 
angiographic substudy. Neither the operator nor the 
patients were blinded to the treatment allocation.
study procedure
Radial or femoral approach was allowed using 6–8F 
guiding catheters. Unfractionated heparin, low- molecular 
weight heparin or bivalirudin and GPIIbIIIa inhibitors 
were used according to local hospital routine. The recom-
mended implantation steps in the simple group were (1) 
predilatation of stenosed areas of the MV to be covered 
by stent, (2) therapeutic dilatation of the SB using a 
balloon with a diameter equal to or greater than the SB 
reference size and (3) stenting of the MV, jailing the SB 
wire. If normal flow (Thrombolysis In Myocardial Infarc-
tion (TIMI) flow=III) was achieved in both the MB and 
the SB, and there was less than 75% residual diameter 
stenosis of the SB ostium, the procedure was terminated. 
Kissing balloon inflation (KBI) was indicated if TIMI flow 
<III, or if the SB ostium had more than 75% diameter 
stenosis after MV stenting. In case of TIMI flow <III after 
KBI, stenting the SB was indicated using a T- stenting12 or 
the culotte technique.13 Final KBI was mandatory if the 
SB was stented.
The culotte implantation technique was recommended 
for planned complex stenting. Other two- stent tech-
niques were allowed at the operator’s discretion except 
classic crush14 and simultaneous kissing stent (SKS) 
techniques.15 Final KBI was mandatory in any two- stent 
procedure.
Lifelong aspirin was prescribed to all patients and 
clopidogrel was indicated for 12 months. Ticlopidine was 
indicated if patients did not tolerate clopidogrel. The 
sirolimus eluting stent ‘Cypher Select+’ (Cordis, USA) 
was the study stent in the first 225 patients and the Xience 
V or Xience Prime, everolimus eluting stents (Abbott, 
USA) were the study stent in the remaining 225 patients. 
The change in study stent during enrolment was a post 
hoc adjustment, as the Cypher stent supply was unex-
pectedly discontinued during the enrolment period. If 
the study stents could not be implanted, another drug- 
eluting stent (DES) or bare metal stent was allowed at the 
discretion of the operator. Different types of DES were 
not allowed in the same vessel.
endpoints
The primary endpoint was the composite of major adverse 
cardiac events (MACE); cardiac death, non- procedural 
myocardial infarction, clinically indicated target lesion 
revascularisation and definite stent thrombosis within 6 
months after the index procedure. Secondary endpoints 
were the composite MACE endpoint at 2 years, all- cause 
mortality, cardiac death, non- procedural myocardial 
infarction, clinically indicated target lesion revascularisa-
tion or target vessel revascularisation, and definite, prob-
able or possible stent thrombosis.
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endpoint definitions
Cardiac death was defined as death from coronary artery 
disease including myocardial infarction, sudden death 
with a possible or definite cardia cause, death from heart 
failure including cardiogenic shock, and death related to 
a cardiac procedure within 28 days from the procedure. 
Cardiac death did not include death due to pulmonary 
embolism, cerebrovascular attacks or other vascular but 
non- cardiac events. Non- procedural myocardial infarc-
tion required evidence of myocardial necrosis by at least 
one of the following criteria: (1) detection of a rise and/
or fall of cardiac biomarkers with at least one value above 
the 99th percentile of the upper reference limit (URL) 
and evidence of ischaemia in the myocardium docu-
mented by either symptoms of ischaemia, ECG changes 
indicative of acute ischaemia (new ST- T changes, new left 
bundle branch block (LBBB), new pathological Q waves 
in the ECG), evidence of new loss of viable myocardium 
or new cardiac wall motion abnormality. (2) Sudden 
and unexpected cardiac death with at least one of the 
following: cardiac arrest, symptoms suggestive of myocar-
dial ischaemia, presumably new ST- segment elevation, 
or new LBBB, and/or evidence of fresh thrombus by 
coronary angiography and/or at autopsy. (3) Patholog-
ical findings suggestive of acute myocardial infarction.16 
Assessment of procedural cardiac biomarkers was recom-
mended. In patients with normal baseline biomarker 
values, elevations of cardiac biomarkers (CK- MB) greater 
than 3×99th percentile URL defined index procedure- 
related myocardial infarction. Patients with stable angina 
pectoris or silent ischaemia were considered to have 
normal baseline markers if values were not assessed. If 
cardiac biomarkers were elevated before the procedure 
and not stable in two samples 6 hours apart, the diagnosis 
of periprocedural myocardial biomarker increase could 
not be made. If biomarker values were stable or falling, a 
20% or more increase of the value in the second sample 
after the procedure was required. Elevations of CK- MB 
greater than 3×99th percentile URL and greater than 
5×99th percentile URL were assessed independently. 
Stent thrombosis was classified as definite, probable or 
possible, and definite stent thrombosis was categorised 
as acute, subacute, late and very late according to the 
Academic Research Consortium(ARC) criteria.17 Target 
lesion revascularisation was defined as repeat revascu-
larisation by percutaneous coronary intervention (PCI) 
or coronary artery bypass surgery of the target lesion 
defined as the stented or balloon- treated segments and 
their 5 mm margins in all three coronary branches.
Quantitative coronary analysis
Coronary angiograms of pre- PCI, post- PCI and 8- month 
follow- up were analysed by the Core laboratory for inter-
ventional coronary imaging, Aarhus University Hospital, 
Denmark and by Pauls Stradins Clinical University 
Hospital, Riga, Latvia, using validated software dedi-
cated to segmental bifurcation analysis (QAngioXA 7.3, 
Medis Medical Imaging, Leiden, The Netherlands). All 
included patients had assessment of pre- PCI and post- PCI 
angiograms and follow- up angiograms were analysed in 
patients completing the 8- month angiographic follow- up. 
Analysis principles of the dedicated bifurcation quantita-
tive coronary analysis (QCA) for the Nordic- Baltic bifur-
cation studies were previously reported.18 The analysed 
segments were the proximal MV, distal MV and SB. 
The bifurcation core segment was analysed in combi-
nation with the proximal MV. The three edge segments 
comprised the 5 mm margins to the stented, or balloon 
treated segments. If the SB was not treated by stent or 
balloon, the first 5 mm of the SB was defined as both the 
lesion and the edge segment. Binary (re)stenosis was 
defined as ≥50% diameter stenosis. All analyses were 
cross- evaluated by the same second observer to ensure 
consistency in methods between the two core laborato-
ries. The QCA was not blinded due to the evident appear-
ance of simple or complex stenting techniques in the 
analysed angiograms.
sample size
The sample size estimate for the primary superiority 
outcome measure of 6- month MACE was based on the 
limited available evidence at conceptualisation of the 
study. With expected MACE rates of 10% in the simple 
group and 3% in the complex group, α=0.05 and 
power=0.80, a sample of 194 patients were required in 
each group (two- sided χ2 test). Sample size was initially 
set to 400 patients in total but was increased during enrol-
ment to 450 patients to accommodate for potential lower 
than expected event rates and patients lost to follow- up.
statistics
Categorical variables are reported as number and 
percentages and were analysed using the χ2 test or Fisher 
exact test if 2×2 cell values were below five. Contin-
uous variables following a Gaussian distribution were 
analysed by the independent sample t- test and presented 
as mean±SD. Non- Gaussian variables were analysed 
by Mann- Whitney U- test and presented as median and 
IQR. Rates of the primary endpoint of 6- month MACE 
and its individual components are presented as risk 
differences. Two- year outcomes are resented as Kaplan- 
Meier estimates, HRs and 95% CIs, and were compared 
by unadjusted Cox regression analysis. The analysis was 
performed according to the intention- to- treat principle. 
Patients lost to follow- up were censored at day of with-
drawal or last contact. Post hoc subgroup analysis was 
performed by Cox regression analysis with test for inter-
action of the subgroup variable and treatment alloca-
tion. Results are given as HR and 95% CI and presented 
by forest plot. Per protocol analysis for 2- year MACE 
excluded any patient that did not receive an MV stent 
and patients in the two- stent group without SB stenting. 
Two- sided p values below 0.05 indicated significance. 
All analyses were performed using STATA V.12 (STATA 
Corp, Texas, USA).
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Figure 1 Patient flow chart. *Numbers in the two groups 
are not balanced at baseline due to block randomisation and 
sites with less than four inclusions. MV, main vessel; SB, side 
branch; FU, follow- up.
Table 1 Baseline clinical characteristics values are 
mean±1 SD or n (%)
Simple 
n=218
Complex 
n=228 P value
Age (years) 64±12 63±11 0.25
Current smoker 41 (18.9%) 48 (21.1%) 0.56
Hypercholesterolaemia 178 (82.0%) 184 (81.1%) 0.79
Hypertension 152 (70.0%) 149 (65.6%) 0.32
Diabetes mellitus 36 (16.5%) 35 (15.4%) 0.74
Family history 108 (50.5%) 107 (47.4%) 0.51
Prior PCI 77 (35.5%) 76 (33.5%) 0.66
Prior CABG 8 (3.7%) 4 (1.8%) 0.21
CCS class ≥2 angina 205 (94.5%) 213 (93.8) 0.98
Indication
  Stable angina pectoris 188 (86.6%) 187 (82.4%) 0.22
  Unstable angina pectoris 28 (12.9%) 38 (16.7) 0.26
  Silent ischaemia 1 (0.5%) 3 (1.3%) 0.34
Antiplatelet therapy
  Aspirin 217 (100%) 227 (100%) 1
  Clopidogrel 216 (99.5) 227 (100%) 1
  GP IIb/IIIa inhibitors 62 (28.6) 83 (36.9.1) 0.06
  Bivalirudin 26 (12.0%) 33 (14.6%) 0.42
CCS, Canadian Cardiovascular Society; GP, glycoprotein receptor.
ResulTs
Patient and lesion characteristics
A total of 450 patients were assigned to simple stenting 
(n=221) or complex stenting (n=229) (figure 1). Two- 
year follow- up was available in 446 patients. Age was 
64±12 vs 63±11 years, 16.3% and 15.3% had diabetes and 
39.1% vs 35.3% had prior coronary artery bypass grafting 
or PCI in simple and complex groups, respectively 
(table 1). The predominant lesion location was LAD and 
diagonal (74.1% vs 76.7%). Reference diameter by visual 
estimate of the MV was 3.5±0.4 mm and 3.4±0.3 mm 
(p=0.02), and the SB reference diameter was 2.9±0.2 mm 
and 2.9±0.2 mm by visual estimate and 2.4±0.5 mm and 
2.5±0.5 mm by QCA in simple and complex groups, 
respectively (table 2). Mean SB stenosis before treatment 
by visual estimate was 74.4%±14.4% and 77.1%±12.1%, 
p=0.04, and by QCA was 44.3%±18.5% and 47.3%±17.6%, 
p=0.95 for simple and complex groups, respectively 
(table 3: QCA for angiographic follow- up group results).
Procedural results
In the simple group, any SB balloon treatment was 
performed in 78.4% of cases and the SB was stented in 
3.7% of cases. In the complex group, the techniques were 
culotte (65.6%), mini crush (21.5%), T- stenting (7.1%) 
or other (5.8%). The SB was stented in 96% and 91% had 
KBI. Reported causes for not stenting the SB in attempted 
two- stent techniques included (1) not able to pass balloon 
into the SB, and (2) not able to pass stents into the SB. 
Residual binary SB stenosis after treatment was 28.0% in 
the simple group and 2.7% (p<0.0001) in the complex 
group. Periprocedural biomarker release was assessable 
in 182 (83%) and 187 (82%) patients in the simple and 
complex stenting groups. The biomarkers were increased 
in 7.7% vs 9.6% (p=0.51) for CK- MB greater than 3×99th 
percentile URL and 5.0% vs 3.7% (p=0.57) for CK- MB 
greater than 5×99th percentile URL in the groups of 
simple and complex stenting, respectively.
outcomes
The primary endpoint of MACE at 6 months was 5.5% 
vs 2.2% (RD 3.2%, 95% CI −0.2 to 6.8, p=0.07) and at 
2 years 12.9% vs 8.4% (HR 0.63, 95% CI 0.35 to 1.15, 
p=0.12) after simple versus complex treatment (figure 2). 
Individual endpoints at 6 months and 2 years are shown 
in figure 3 and table 4. Per protocol analysis for 2- year 
MACE was 12.9% in 218 vs 8.7% in 219 patients (p=0.16). 
Angina pectoris by Canadian Cardiovascular Society 
score ≥II at 2- year follow- up was 3.9% in the simple group 
and 4.1% in the complex group (RD −0.2%, 95% CI −4.0 
to 3.4, p=0.89). In the subgroup treated by first gener-
ation DES, the rate of 2- year MACE rate was 12.9% vs 
10.3% (HR 0.77, 95% CI 0.36 to 1.67, p=0.51) and after 
treatment by newer generation DES MACE was 12.0% vs 
5.6% (HR 0.45, 95% CI 0.17 to 1.17, p=0.10) after simple 
versus complex treatment (figure 2). Other subgroup 
results are presented in figure 4. Eight- month angio-
graphic follow- up was completed in 307 patients assigned 
to simple (n=153) or complex stenting (n=154). After the 
index procedure, SB binary residual stenosis was 28.0% vs 
2.7% (p<0.001). After 8 months, the binary (re)stenosis 
rate was 1.3% vs 0.7% (p=0.56) in the proximal MV, 1.3% 
vs 1.3% (p=0.99) in the distal MV and 20.3% vs 5.2% 
(p<0.001) in the SB after simple versus complex stenting, 
respectively.
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Table 2 Lesion and procedural characteristics
Simple n=218 Complex n=228 P value
LVEF (%) 57±6 56±7 0.10
Lesion location     
  Left anterior descending artery 161 (74.2%) 174 (76.7%) 0.55
  Circumflex artery 36 (16.6%) 40 (17.6%) 0.77
  Right coronary artery 14 (6.5%) 9 (4.0%) 0.24
  Left main stem 6 (2.77%) 3 (1.3%) 0.28
Calcification visible by angiography 105 (48.4%) 99 (43.6%) 0.31
Proximal tortuosity 6 (2.8%) 16 (7.0%) 0.04
Angulation less than 70 degrees 107 (49.3%) 111 (48.9%) 0.93
Mean lesion length*, mm     
  Main vessel 20.8±9.9 19.5±8.9 0.15
  Side branch 6.4±4.1 7.7±4.9 <0.0001
Proximal reference diameter*, mm     
  Main vessel 3.5±0.4 3.4±0.3 0.02
  Side branch 2.9±0.2 2.9±0.2 0.16
Side branch predilated 140 (64.2%) 177 (78.0%) –
Main vessel stented 238 (99.6) 238 (100) 1.00
Side branch stented 8 (3.7%) 219 (96.5%) –
Length of stented main vessel segment*, mm 25.0±9.5 24.3±9.6 0.34
Length of stented side branch segment*, mm 13([8:15) 9(6:13) –
Side branch predilatation or final kissing balloon inflation 171 (78.4%) – –
Final kissing balloon inflation 79 (36.1%) 208 (91.2%) –
Treatment successful† 212 (97.7%) 226 (98.7%) 0.14
Procedure time, min 41.8±33.2 67.9±27.6 <0.0001
Fluoroscopy time, min 13.9±8.8 22.8±12.8 <0.0001
Contrast volume, mL 187±81 231±86 <0.0001
Values are mean±1 SD or n (%).
*By visual estimate.
†Residual stenosis <30%, of main vessel and Thrombolysis InMyocardial Infarction (TIMI) III flow in side branch.
FKBI, final kissing balloon inflation; LVEF, left ventricular ejection fraction.
dIsCussIon
Main findings
In the randomised Nordic- Baltic Bifurcation Study IV, 
treatment of bifurcation lesions involving a large SB 
resulted in 6- month MACE of 5.5% vs 2.2% and 2- year 
MACE of 13.2% vs 8.3%, both statistically non- significant, 
after treatment by the simple provisional SB stenting 
technique or planned two- stent techniques, respectively. 
Two- stent procedures were associated with less angio-
graphic SB stenosis at 8- month follow- up but procedure 
time, fluoroscopy time, use of contrast and use of stents 
were all increased in the two- stent group.
one or two stents for bifurcations
The study addresses one of the main questions in coronary 
bifurcation treatment; routine stenting of both MV and SB 
or stenting of the MV only with optional SB treatment if 
reduced flow or a severe stenosis is detected after MV stent 
implantation. Earlier randomised clinical trials on simple 
versus complex bifurcation stenting, with the exception 
of the DKCRUSH- II study,9 were in favour of the simple 
one- stent strategy.4–7 19 In the BBC ONE study, there were 
more myocardial infarctions at 9 months in the two- stent 
group (3.6% vs 11.2%; p=0.001) driven by periprocedural 
biomarker elevation.2 In the 5- year follow- up in the Nordic- 
Baltic Bifurcation Study I, there was no statistically signif-
icant difference in MACE after simple versus complex 
strategies (15.8% vs 21.8%; p=0.12) but an indication of 
more favourable long- term results after simple stenting 
using first generation DES.3 In the DKCRUSH- II study, 
the double kissing crush two- stent technique reduced new 
revascularisations as compared with optional SB stenting 
at 5 years.20 However, in that study, the difference between 
the study groups was possibly influenced by a study- related 
angiographic follow- up, and the 1- year event rates in the 
two- stent group were numerically higher than in the one- 
stent group of Nordic- Baltic I and IV.
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Table 3 Quantitative coronary angiography at baseline and at 8- month angiographic follow- up in a subgroup of patients 
randomised to simple versus complex coronary bifurcation stenting
Segment
Proximal main vessel Distal main vessel Side branch
Simple 
n=153
Complex 
n=154 P value
Simple 
n=153
Complex 
n=154 P value
Simple 
n=153
Complex 
n=154 P value
In- stent minimal luminal diameter, mm
Pre- PCI 1.29±0.55 1.41±0.60 0.96 1.43±0.55 1.43±0.58 0.51 1.43±0.69 1.21±0.46 0.0008
Post- PCI 3.05±1.46 2.84±1.48 0.11 2.45±0.42 2.51±0.41 0.89 1.59±0.65 2.10±0.37 <0.001
Follow- up 2.76±0.54 2.65±0.56 0.06 2.48±0.49 2.42±0.53 0.30 1.77±0.70 2.07±0.51 <0.001
Reference diameter, mm
Baseline 3.13±0.47 3.20±0.57 0.86 2.57±0.46 2.61±0.54 0.74 2.33±0.49 2.40±0.49 0.59
In- stent diameter stenosis, %
Pre- PCI 59±16 57±17 0.17 40±20 43±22 0.25 43±18 49±17 0.99
Post- PCI 11±9 8±7 0.005 11±9 11±9 0.49 36±19 17±11 <0.001
Follow- up 12±11 10±8 0.01 12±10 15±12 0.97 32±20 21±17 <0.001
In- stent late lumen loss, mm
  0.27±1.48 0.08±1.52 0.14 −0.10±0.45 −0.03±0.47 0.89 −0.20±0.66 0.03±0.52 0.99
In- segment binary restenosis, n (%)
Follow- up 2 (1.3) 1 (0.7) 0.56 2 (1.3) 2 (1.3) 0.99 31 (20.3) 8 (5.2) <0.001
Binary restenosis: ≥50% diameter stenosis at 8- month follow- up.
Fisher’s exact test, χ2 test or independent samples t- test were used.
*In- stent segments included the stented areas of the main vessel and or the first 5 mm of the side branch.
Compared with earlier studies, Nordic- Baltic IV was 
the first randomised study comparing one- stent versus 
two- stent strategies in bifurcations involving large SB 
(≥2.75 mm) with angiographic significant disease. 
Although our MACE rate was higher in the simple group 
(12.8%) compared with the complex group (8.3%), 
mostly driven by a statistically insignificant difference in 
target lesion revascularisation (9.2% vs 6.1%, p=0.23), we 
failed to document a significant advantage in the use of 
complex two- stent techniques. However, the numerically 
lower MACE rates do suggest that two- stent procedures 
were at least safe in the treatment of patients with signif-
icant SB disease.
Two-stent techniques
Our good results using two- stent techniques are in line 
with the DK- CRUSH II results.20 Still, the double kissing 
crush technique applied in the DK- CRUSH study series 
was later found to be superior to culotte stenting in 
patients with unprotected LMCA disease by the same 
group of investigators21 leading to the recent ESC recom-
mendation of the double kissing crush technique for the 
treatment of Medina Class 1.1.1 distal LMCA bifurcation 
lesions.22 In Nordic- Baltic IV, applying predominantly 
the culotte and mini- crush techniques, the success rate 
of KBI was 92%, whereas the success rate of KBI using 
the double kissing crush technique was 96%–100% in 
the DK- CRUSH study series.8 17–19 KBI in culotte was 
successful in 96 of 97 cases in the 200 pts EBC TWO trial 
but still yielded similar outcome compared with provi-
sional T stenting for large bifurcations.20 We do not know 
if the relatively favourable results in the two- stent group 
of Nordic- Baltic IV might have been further improved 
using the double kissing crush technique.
one-stent technique
In the provisional SB stenting group, the strict cross- over 
criteria resulted in SB stenting in only 3.7% of cases. The 
numerically increased rate of target lesion revascular-
isation suggests that some SBs might have been under-
treated by relying solely on visual assessed diameter 
stenosis and reduction in TIMI flow for SB stenting. Large 
SBs may supply a larger territory and the increased rate 
of angiographic SB restenosis after simple stenting may 
indicate a clinical relevant difference between the two 
strategies. We were not able to demonstrate a significant 
difference for longer SB lesions >5 mm likely due to the 
small subsample. Still, the numerical difference (16.5% 
vs 9.6%) could indicate that longer lesions more often 
require SB stenting which would be in line with other 
reports.23 24 Previous studies on simple versus complex 
stenting documented a large variation, from 2% to 31%, 
in SB stenting using the simple optional SB stenting tech-
nique.2 6 9 10 25 Currently, the generally accepted criteria 
for SB intervention in coronary bifurcations are based on 
angiographic indication of reduced flow, stenosis severity 
>75% DS, and SB stenosis length >5 mm,26 but physiolog-
ical measurements such as fractional flow reserve assess-
ment27 or use of intravascular ultrasound28 and optical 
coherence tomography29 imaging techniques might 
improve our angiography- based decisions on indication 
for SB revascularisation.
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Figure 2 Kaplan- Meier curve for major adverse cardiac events (MACE). Clinical event curves showing MACE rates until 
2 years.
In Nordic- Baltic IV, it was recommended to perform a 
‘therapeutic predilation’ of the SB with a balloon sized 
according to the SB reference diameter. Pan et al demon-
strated that a similar strategy reduced both the rate of 
SB TIMI flow <III and the need for subsequent KBI and 
the SB predilation did not impair SB rewiring.30 The SB 
predilation rate in Nordic- Baltic IV was 64%, and the total 
rate of SB balloon dilatation was 78%, leaving 22% in the 
simple one- stent group without any SB treatment. This 
lack of SB intervention might indicate a suboptimal treat-
ment, although it is unknown if the SB in these patients 
was left with a functionally significant stenosis.
In Nordic- Baltic IV, the mean lesion length in the SB 
was 5.5 mm compared with 10 mm in the BBK study4 and 
15 mm in the DKCRUSH II study.20 The longer SB lesions 
likely contributed to the higher rate of cross over to SB 
stenting in the simple groups in these studies of 19% 
and 28%, respectively. The authors of the present study 
believe that it makes little sense to randomise patients 
with long significant lesions in a large SB, in one- stent 
versus two- stent technique studies as such SB lesions may 
require stenting in any case.
The study was initiated before introduction and recom-
mendation of the proximal optimisation technique (POT)31 
to improve proximal stent apposition and facilitate wiring 
of a SB jailed by a stent.26 Despite the potential advantages 
of this additional procedural step,32–34 the clinical impor-
tance has yet to be fully determined35 and optimal execu-
tion clarified.36 It is therefore uncertain to which extent the 
lack of systematic postdilatation of the proximal segment 
negatively impacted our results, and if POT has different 
effects in simple and complex techniques.
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Figure 3 Kaplan- Meier curves for clinical endpoints. Clinical event curves for cardiac death, non- procedural myocardial 
infarction and target lesion revascularisation until 2 years.
 o
n
 M
ay 28, 2020 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000947 on 19 January 2020. Downloaded from
 
9Kumsars I, et al. Open Heart 2020;7:e000947. doi:10.1136/openhrt-2018-000947
Interventional cardiology
Table 4 The individual components of MACE and clinical outcomes at 24 months
Provisional side 
branch stenting 
(Simple)
Two- stent technique 
(Complex)
Risk difference
(95% CI) P value
Events at 6 months Follow- up in 220 
patients
Follow- up in 228 
patients
MACE 12 (5.5%) 5 (2.2%) 3.2% (−0.2 to 6.8) 0.07
All- cause mortality 0 (0%) 1 (0.4%) −0.4% (−1.3 to 0.4) 0.33
Cardiac mortality 0 (0%) 0 (0%) 0.0% (0.0 to 0.0) 1.00
Myocardial infarction* 6 (2.7%) 3 (1.3%) 1.4% (−1.2 to 4.0) 0.29
Target- lesion revascularisation 9 (4.1%) 4 (1.8%) 2.3% (−0.8 to 5.5) 0.14
Target- vessel revascularisation 10 (4.6%) 4 (1.8%) 2.8% (−0.4 to 6.0) 0.11
Definite stent thrombosis 2 (0.9%) 2 (0.9%) 0.0% (−1.7 to 1.8) 0.97
Events at 24 months† Follow- up in 218 
patients
Follow- up in 228 
patients
HR (95% CI) P value
MACE 12.9% (28) 8.4% (19) 0.63 (0.35 to 1.13) 0.12
All- cause mortality 2.3% (5) 2.2% (5) 0.94 (0.28 to 3.31) 0.94
Cardiac mortality 0.9% (2) 0.9% (2) 0.96 (0.13 to 6.8) 0.96
Myocardial infarction* 5.1% (11) 3.1% (7) 0.60 (0.23 to 1.55) 0.30
Target- lesion revascularisation 9.2% (20) 6.2% (14) 0.66 (0.33 to 1.30) 0.23
Target- vessel revascularisation 10.5% (23) 6.6% (15) 0.61 (0.32 to 1.17) 0.13
      Risk difference (95% CI)
CCS class ≥2 angina‡ 8 (3.9%) 9 (4.1%) −0.2% (−4.0 to 3.4) 0.89
Stent thrombosis‡     
  Definite, any (0–2 years) 3 (1.4%) 3 (1.3%) 0.1% (−2.0 to 2.2) 0.96
  Definite, acute (0–1 day) 1 (0.5%) 1 (0.4%) 0.0% (−1.2 to 1.3) 0.98
  Definite, subacute (2–30 days) 1 (0.5%) 1 (0.4%) 0.0% (−1.2 to 1.3) 0.98
  Definite, late (1–12 months) 0 (0.0%) 0 (0.0%) 0.0% (0.0 to 0.0) –
  Definite, very late (12–24 
months)
1 (0.5%) 1 (0.4%) 0.0% (−1.2 to 1.3) 0.98
  Definite or probable, any (0–2 
years)
4 (1.8%) 3 (1.3%) 0.5% (−1.7 to 2.8) 0.66
  Definite, prob. or poss., any 
(0–2 years)
6 (2.8%) 5 (2.2%) 0.6% (−2.3 to 3.4) 0.70
*Non- procedure related. Values are n (%).
†Twenty- four month results are given as Kaplan- Meier estimates and (n).
‡Results are given as n (%), risk difference and 95% CI.
MACE, major adverse cardiac events .
Procedural complexity
The provisional stenting approach was performed using 
less contrast and less radiation in shorter procedures, as 
in previous studies.6 10 25 These procedural characteristics 
of the simple one- stent technique may be of considerable 
importance in selecting strategy, especially in high- risk 
and frail elderly patients. At the same time, the presented 
2- year results by the two strategies do not contradict the 
choice of a two- stent strategy in selected cases with func-
tional significant SB stenosis or in case of high risk of SB 
compromise, difficult SB access or anticipated difficult 
access after MV stent implantation.
duration of dual antiplatelet therapy
The recommended duration of dual antiplatelet therapy 
(DAPT) was 12 months in Nordic- Baltic IV independent 
of treatment indication and complexity of treatment. 
The present ESC recommendation is 6 months DAPT 
after PCI indicated by stable angina pectoris with the 
provision that prolonged DAPT may be considered after 
complex PCI including two- stent bifurcation treatment.37 
We cannot rule out a minor positive effect on outcomes 
for the two- stent group compared with patients treated 
with one- stent techniques at the expense of increased 
bleeding risk in both groups.38 Our results, however, 
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Figure 4 Subgroup analyses of the primary composite endpoint. Event rates are Kaplan- Meier estimates by time- to- event of 
the composite endpoint for major adverse cardiovascular events (MACE). The likelihood of interaction of the subgroup variable 
and allocated treatment is given by the p value for interaction. SB, side branch; DS%, diameter stenosis in %. Angiographic 
parameters are by visual estimation.
indicate that such potential positive effect for two- stent 
techniques may be countered by using first generation 
DES in half of the patients in this trial. An individualised 
assessment of treatment complexity, treatment result and 
the patients perceived bleeding risk is recommended 
when determining the optimal duration of DAPT.37
First and newer generation des
During the first half of enrolled patients, the first gener-
ation Cypher Select+ was used as stent, while the newer 
generation Xience stent was used as stent in the latter 
part. The equal results of Cypher and Xience in the 
simple group but more than 50% reduction in MACE 
in the complex group after treatment by newer gener-
ation stent compared with first- generation stents may 
indicate an improved safety of two- stent techniques using 
newer generation stents. This could indicate an impor-
tant advancement in the safety of two- stent techniques 
that may be associated with increased mortality when 
performed with first- generation DES.19 The hypersensi-
tive reaction induced in some patients by the polymer 
of first- generation stents39 may have been aggravated by 
higher strut density in overlapping40 and crushed stent 
segments, and the closed cell design might have limited 
the expansion of stents implanted through stent cells 
as in the culotte technique.41 The newer generation 
Xience stent features a more biocompatible polymer and 
open cell design and thus might provide a larger safety 
gain in two- stent techniques than in single stent tech-
niques.42 43 It is possible that due to the favourable results 
in the complex group by second generation DES and the 
consistent documentation of double kissing crush as a 
superior two- stent technique, we might have underesti-
mated the positive effect of the combination of best stent 
and best technique for two- stent treatment. On the other 
hand, less conservative SB intervention criteria might 
have reduced the rate of early target lesion revasculari-
sation, although such more liberal SB treatment strategy 
during provisional stenting is not backed by published 
results. Recent guidelines recommend PCI for treatment 
of LMCA stenosis in patients with low (≤22) SYNTAX 
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score.22 This has increased the focus on optimal bifurca-
tion stenting as 80%–85% of LMCA treatments involve 
the distal LMCA bifurcation.44 45 In Nordic- Baltic IV, only 
a small portion of cases were treated for distal LMCA 
bifurcation stenosis. Thus, extrapolation of our results to 
this lesion subset should be done with caution given the 
specific technical challenges in distal LMCA bifurcation 
PCI.46
study limitations
Enrolled patients had rather short SB lesions, thus 
limiting conclusions to this relevant subset of bifurcation 
lesions. The use of angiographic SB inclusion criteria 
might have led to inclusion of some patients with phys-
iologically insignificant SB disease favouring the simple 
one- stent technique, and despite randomisation, the SB 
diameter stenosis before treatment was less severe in the 
simple group indicating a potentially lower overall risk 
in this group. The sample size estimate for Nordic- Baltic 
IV was based on the limited available evidence at time of 
conceptualisation and we cannot exclude that the study 
was underpowered to detect a true difference between the 
two treatment strategies. It was strongly recommended to 
perform only clinically driven and fractional flow reserve 
(FFR)- guided revascularisation in the follow- up period 
but the planned 8- month angiographic follow- up might 
still have led to more revascularisation. The plateau of 
the MACE curves before the increase in revascularisation 
seen around the 8- month time point could also reflect 
that patients truly requiring revascularisation awaited the 
planned follow- up and some cases were treated before 
the patient would normally seek a doctor. As the safety 
of the techniques studied might change over time, the 
reported 2- year results added clinically relevant informa-
tion to this report but very long- term follow- up is needed 
to make a final assessment of one versus two stents for 
coronary bifurcation treatment.
ConClusIon
In the treatment of coronary bifurcation lesions involving 
a large SB with ostial stenosis, routine stenting of both 
the MV and the SB did not improve outcome significantly 
compared with treatment by the simpler MV stenting 
technique after 2 years.
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